{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:28:12Z","timestamp":1790400492967,"version":"4.1.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/mlr.0b013e318245a160","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T04:05:40Z","timestamp":1326427540000},"page":"466-478","source":"Crossref","is-referenced-by-count":191,"title":["Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors"],"prefix":"10.1097","volume":"50","author":[{"given":"Stacie B.","family":"Dusetzina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley S.","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Ray","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiden A.","family":"Huskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig F.","family":"Garfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Caleb","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20210211","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaci.2005.10.031","article-title":"Black box 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefitrisk.","volume":"117","author":"Murphy","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R5-2-20210211","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2165\/11539040-000000000-00000","article-title":"Public pharmacovigilance communication: a process calling for evidence-based, objective-driven strategies.","volume":"33","author":"Bahri","year":"2010","journal-title":"Drug Saf"},{"key":"R6-2-20210211","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1539-6924.1995.tb00308.x","article-title":"Risk perception and communication unplugged: twenty years of process.","volume":"15","author":"Fischhoff","year":"1995","journal-title":"Risk Anal"},{"key":"R8-2-20210211","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev.pu.15.050194.001545","article-title":"Efficacy of labeling of foods and pharmaceuticals.","volume":"15","author":"Vicusi","year":"1994","journal-title":"Annu Rev Public Health"},{"key":"R9-2-20210211","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.sapharm.2009.02.005","article-title":"Health care consequences of black-box warnings for antidepressants in the United States and Canada.","volume":"6","author":"Nagar","year":"2010","journal-title":"Res Social Adm Pharm"},{"key":"R10-2-20210211","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/cap.2007.0049","article-title":"Antidepressant prescribing practices for the treatment of children and adolescents.","volume":"18","author":"Bhatia","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R12-2-20210211","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.puhe.2008.04.009","article-title":"Selective serotonin re-uptake inhibitor warnings and trends in exposures reported to poison control centres in Texas.","volume":"122","author":"Forrester","year":"2008","journal-title":"Public Health"},{"key":"R13-2-20210211","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/appi.ajp.2007.07030454","article-title":"Early evidence on the effects of regulators suicidality warnings on SSRI prescriptions and suicide in children and adolescents.","volume":"164","author":"Gibbons","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R14-2-20210211","first-page":"17","article-title":"Changes in antidepressant medications prescribing trends in children and adolescents in Hawaii following the FDA black box warning.","volume":"69","author":"Hassanin","year":"2010","journal-title":"Hawaii Med J"},{"key":"R15-2-20210211","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/archpedi.161.7.690","article-title":"Effect of regulatory warnings on antidepressant prescribing for children and adolescents.","volume":"161","author":"Kurian","year":"2007","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R16-2-20210211","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1176\/ajp.2007.164.6.884","article-title":"Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs.","volume":"164","author":"Libby","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R17-2-20210211","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archgenpsychiatry.2009.46","article-title":"Persisting decline in depression treatment after FDA warnings.","volume":"66","author":"Libby","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"R18-2-20210211","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1176\/appi.ajp.2007.07010205","article-title":"Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs.","volume":"165","author":"Morrato","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R19-2-20210211","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.64.4.466","article-title":"Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States.","volume":"64","author":"Nemeroff","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"R20-2-20210211","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archgenpsychiatry.2007.5","article-title":"Effects of Food and Drug Administration warnings on antidepressant use in a national sample.","volume":"65","author":"Olfson","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"R21-2-20210211","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jadohealth.2006.12.006","article-title":"Pediatric primary care providers and adolescent depression: a qualitative study of barriers to treatment and the effect of the black box warning.","volume":"40","author":"Richardson","year":"2007","journal-title":"J Adolesc Health"},{"key":"R22-2-20210211","first-page":"30","article-title":"Decreased use of antidepressants in youth after US Food and Drug Administration black box warning.","volume":"6","author":"Singh","year":"2009","journal-title":"Psychiatry"},{"key":"R23-2-20210211","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/MLR.0b013e3181ef9d2b","article-title":"Impact of the 2004 Food and Drug Administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression.","volume":"48","author":"Valluri","year":"2010","journal-title":"Med Care"},{"key":"R24-2-20210211","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1176\/appi.ajp.2007.07010007","article-title":"Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs.","volume":"164","author":"Valuck","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R25-2-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.1048","article-title":"Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program.","volume":"14","author":"Cluxton","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R26-2-20210211","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jama.286.7.831","article-title":"Liver enzyme monitoring in patients treated with troglitazone.","volume":"286","author":"Graham","year":"2001","journal-title":"JAMA"},{"key":"R27-2-20210211","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc09-1834","article-title":"Changes in glitazone use among office-based physicians in the U.S., 2003-2009.","volume":"33","author":"Cohen","year":"2010","journal-title":"Diabetes Care"},{"key":"R28-2-20210211","first-page":"e111","article-title":"Clinical consequences of disseminating the rosiglitazone FDA safety warning.","volume":"16","author":"Orrico","year":"2010","journal-title":"Am J Manag Care"},{"key":"R29-2-20210211","doi-asserted-by":"crossref","first-page":"523","DOI":"10.18553\/jmcp.2008.14.6.523","article-title":"Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.","volume":"14","author":"Starner","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"R30-2-20210211","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/pds.1819","article-title":"Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazone.","volume":"18","author":"Stewart","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R31-2-20210211","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/pds.830","article-title":"Impact of cisapride label changes on codispensing of contraindicated medications.","volume":"12","author":"Guo","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R32-2-20210211","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1001\/jama.284.23.3036","article-title":"Contraindicated use of cisapride: impact of food and drug administration regulatory action.","volume":"284","author":"Smalley","year":"2000","journal-title":"JAMA"},{"key":"R33-2-20210211","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1067\/mcp.2002.129503","article-title":"The impact of wording in Dear doctor letters and in black box labels.","volume":"72","author":"Weatherby","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R34-2-20210211","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/pds.592","article-title":"Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of Dear doctor letters.","volume":"10","author":"Weatherby","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R35-2-20210211","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.clinthera.2009.05.008","article-title":"Retrospective claims study of fluticasone propionatesalmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.","volume":"31","author":"Friedman","year":"2009","journal-title":"Clin Ther"},{"key":"R36-2-20210211","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1081-1206(10)60529-7","article-title":"Differences in physicians self-reported knowledge of, attitudes towards, and responses to the black box warning on long-acting beta-agonists.","volume":"103","author":"Karpel","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R37-2-20210211","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2146\/ajhp070685","article-title":"Use of controller medications in patients initiated on a long-acting beta2-adrenergic agonist before and after safety alerts.","volume":"65","author":"Stockl","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"R38-2-20210211","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jclinane.2007.08.003","article-title":"The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia.","volume":"20","author":"Habib","year":"2008","journal-title":"J Clin Anesth"},{"key":"R39-2-20210211","first-page":"3","article-title":"The effects of the FDA warning on the use of droperidol by U.S. Emergency physicians.","volume":"4","author":"Richards","year":"2003","journal-title":"Cal J Emerg Med"},{"key":"R40-2-20210211","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jclinane.2007.02.008","article-title":"Changing patterns of postoperative nausea and vomiting prophylaxis drug use in an academic anesthesia practice.","volume":"19","author":"Wax","year":"2007","journal-title":"J Clin Anesth"},{"key":"R41-2-20210211","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/archinternmed.2009.456","article-title":"Impact of FDA black box advisory on antipsychotic medication use.","volume":"170","author":"Dorsey","year":"2010","journal-title":"Arch Intern Med"},{"key":"R42-2-20210211","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archgenpsychiatry.2009.179","article-title":"Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADAAPA recommendations for second-generation antipsychotic drugs.","volume":"67","author":"Morrato","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"R43-2-20210211","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpediatrics.2010.48","article-title":"Metabolic screening in children receiving antipsychotic drug treatment.","volume":"164","author":"Morrato","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R44-2-20210211","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0009-9236(97)90185-5","article-title":"Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin.","volume":"61","author":"Burkhart","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R46-2-20210211","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03530410053033","article-title":"Use of terfenadine and contraindicated drugs.","volume":"275","author":"Thompson","year":"1996","journal-title":"JAMA"},{"key":"R47-2-20210211","first-page":"321","article-title":"Possible interactions with terfenadine and asetmizole.","volume":"160","author":"Zelnich","year":"1994","journal-title":"West J Med"},{"key":"R48-2-20210211","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/pds.1886","article-title":"Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions.","volume":"19","author":"Pamer","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R49-2-20210211","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1592\/phco.24.11.978.36136","article-title":"Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone.","volume":"24","author":"Wilkinson","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R50-2-20210211","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.acap.2009.07.002","article-title":"Physician and parent response to the FDA advisory about use of over-the-counter cough and cold medications.","volume":"10","author":"Garbutt","year":"2010","journal-title":"Acad Pediatr"},{"key":"R51-2-20210211","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.contraception.2008.07.022","article-title":"Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians.","volume":"78","author":"Paschall","year":"2008","journal-title":"Contraception"},{"key":"R52-2-20210211","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1310\/hpj4505-389","article-title":"Promethazine prescribing patterns in pediatric inpatients younger than two years before and after the product black box warning.","volume":"45","author":"Kessler","year":"2010","journal-title":"Hospital Pharmacy"},{"key":"R53-2-20210211","doi-asserted-by":"crossref","first-page":"420","DOI":"10.18553\/jmcp.2007.13.5.420","article-title":"Telithromycin: the perils of hasty adoption and persistence of off-label prescribing.","volume":"13","author":"Gleason","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"R54-2-20210211","doi-asserted-by":"crossref","first-page":"291e1","DOI":"10.1016\/j.ajog.2007.09.009","article-title":"Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy.","volume":"198","author":"Bowen","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"R55-2-20210211","first-page":"33","article-title":"The unintended effects of a boxed warning.","volume":"2","author":"Ceilley","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"R56-2-20210211","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/pds.961","article-title":"Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants.","volume":"14","author":"Shatin","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R58-2-20210211","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00004583-200207000-00009","article-title":"A study of compliance with FDA recommendations for pemoline.","volume":"41","author":"Willy","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R61-2-20210211","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/humupd\/5.6.621","article-title":"The public health implications of the 1995 pill scare.","volume":"5","author":"Furedi","year":"1999","journal-title":"Hum Reprod Update"},{"key":"R63-2-20210211","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1503\/cmaj.1031920","article-title":"Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results.","volume":"172","author":"Hatala","year":"2005","journal-title":"CMAJ"},{"key":"R65-2-20210211","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MLR.0b013e3181d60408","article-title":"Clinical prescribing (and off-label use) in a second-best world.","volume":"48","author":"Alexander","year":"2010","journal-title":"Med Care"},{"key":"R66-2-20210211","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1056\/NEJMp1011042","article-title":"Responding to an FDA warninggeographic variation in the use of rosiglitazone.","volume":"363","author":"Shah","year":"2010","journal-title":"N Engl J Med"},{"key":"R67-2-20210211","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMp0903764","article-title":"The FDA as a public health agency.","volume":"360","author":"Hamburg","year":"2009","journal-title":"N Engl J Med"},{"key":"R68-2-20210211","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMp0905466","article-title":"Managing drug-risk informationwhat to do with all those new numbers.","volume":"361","author":"Avorn","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Medical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MLR.0b013e318245a160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:42Z","timestamp":1786048062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005650-201206000-00002"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mlr.0b013e318245a160","relation":{},"ISSN":["0025-7079"],"issn-type":[{"value":"0025-7079","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}